24 Month, Multicenter, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-Controlled Certican With Reduced Neoral Versus 3.0g MMF With Standard Dose Neoral In De Novo Heart Transplant Recipients

ID Number 06-0283

Principal Investigator(s)
Sean P Pinney

Department(s) or Division(s)


This trial will examine the impact of everolimus and reduced cyclosporine on efficacy and renal function compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients. ClinicalTrials.gov Identifier: NCT00300274

Contact Information
Sean Pinney
(212) 241-7300 

Recruiting Patients: No